Clinigen Announces Strategic Partnership with Tepsivo
London, 27 January 2025 – Clinigen, the global specialist pharmaceutical services company, today announced a strategic partnership with Tepsivo, a pioneering global digital Pharmacovigilance (PV) services provider. As part of the partnership, Clinigen has acquired a minority stake in Tepsivo.
At the heart of Tepsivo’s offering is its cutting-edge PV platform and proprietary automated PV software powered by artificial intelligence and other digital innovations. The complete PV solution has been designed as a single integrated platform, and leverages Tepsivo’s established global network and central coordination to provide a more cost-effective, modern, and efficient approach in managing global PV systems. Tepsivo help pharmaceutical and biotechnology clients across multiple regions to improve compliance and optimise pharmacovigilance operations.
“This strategic partnership reflects our confidence in Tepsivo’s automated pharmacovigilance platform and its ability to modernise pharmacovigilance services,” said Nihad Hasagic, SVP of Strategic Initiatives at Clinigen. “Together, we are not only expanding the range of digital PV solutions available to our clients but also paving the way for a future where technology drives more efficient drug development.”
Tepsivo co-founder Dominik Hodbod said: “Tepsivo was built to redefine pharmacovigilance by integrating digital innovations, including advanced AI, into every aspect of our platform to provide the highest level of compliance at the lowest cost. By partnering with Clinigen we can accelerate our mission to deliver innovative digital PV solutions to a global audience, empowering clients with tools that enable scientists to focus on real science and improve compliance and patient safety.”
Merav Edan, SVP of PV, Regulatory Affairs, and Medical Information Operations at Clinigen, added: “Tepsivo’s technology allows us to offer clients an additional truly modern and future-proof approach to pharmacovigilance services. By combining their innovative platform with Clinigen’s deep expertise in pharmacovigilance, regulatory affairs, and medical information within our Lifecycle Services business unit, we’re equipping clients with the solutions they need to stay ahead in an increasingly complex regulatory landscape.”
This strategic collaboration reinforces the shared commitment of Clinigen and Tepsivo: a world where digital innovation drives efficiency and modernisation within PV programs, enabling faster and more effective safety monitoring and regulatory compliance.
For media enquiries, please contact:
Email: clinigen@fightorflight.com
Notes to Editors
About Clinigen
Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to accelerate access to medicines for patients in every corner of the globe. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa, and the Asia Pacific. Clinigen has more than 1,100 employees across five continents in 15 countries and provides access in more than 130 countries every year.
For more information on Clinigen, please visit http://www.clinigen.com.
About Tepsivo
Tepsivo is a specialized services provider offering pharmacovigilance full service, powered by inhouse-built software, to pharmaceutical and biotech companies globally. Its mission is to overhaul the world of pharmacovigilance and bring the field to a modern-day industry and value-based healthcare. Tepsivo is headquartered in Helsinki, Finland with a subsidiary in Prague, Czech Republic. The firm’s core team operates in Europe with support of a network of local consultants in more than 150 countries.
For more information on Tepsivo, please visit https://www.tepsivo.com/